A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
Overview
- Phase
- Phase 2
- Intervention
- Syntocinon
- Conditions
- Frontotemporal Dementia
- Sponsor
- Lawson Health Research Institute
- Enrollment
- 112
- Locations
- 11
- Primary Endpoint
- Change in Neuropsychiatric Inventory (NPI) apathy/indifference domain score
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The purpose of this study is to assess the safety, tolerability and effects on behaviour of Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive saline substance that contains no medication) in participants with frontotemporal dementia/Pick's disease. This study will take place in approximately 15 centres across Canada and the United States. Approximately 112 patients in total will be enrolled in this study. In the first phase we will examine which of three different dosing schedules of oxytocin may be more effective. In the second phase of the study, patients entering the study will be randomized to the oxytocin dosing schedule that appeared most effective in the first phase.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of probable FTD (behavioural variant FTD, FTD-semantic subtype or FTD-Progressive Nonfluent Aphasia) with supportive brain imaging (centrally rated frontotemporal atrophy score of 2 or greater on brain MRI or CT) or known FTD causing genetic mutation.68
- •Current symptoms of social apathy/indifference as measured by NPI apathy/indifference severity subscale score \>= 2 indicating the presence of moderate to marked levels of apathy/indifference.
- •Study partner who consents to study participation and who cares for/visits the patient daily for at least 3 hours/day and who can administer all trial medications.
- •FTLD-CDR score 0-
- •Stable baseline medications related to cognition or behaviour for \>=30 days such as acetylcholinesterase inhibitors, memantine, anti-depressants, antipsychotic agents, other mood stabilizers, benzodiazepines.
- •Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from their substitute decision maker).
Exclusion Criteria
- •History of stroke, other neurologic or psychiatric disorder other than FTD that is considered to better account for behavioural symptoms.
- •History of a myocardial infarction within the last two years or congestive heart failure.
- •Current uncontrolled hypertension
- •Current bradycardia (rate \< 50 beats per minute/bpm) or tachycardia (rate \> 100 bpm)
- •Current hyponatremia (Na \<135 mEq/L)
- •Current use of topical prostaglandin medications applied to the cervix.
- •Females who are pregnant or breastfeeding, or planning to conceive within the study period.
- •Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug, whichever is longer.
- •Participant has speech difficulties that in the opinion of the investigator would be incompatible with neuropsychology and safety assessments
- •History of cancer except:
Arms & Interventions
Low Dose
Intervention: Syntocinon
Medium Dose
Intervention: Syntocinon
High Dose
Intervention: Syntocinon
Outcomes
Primary Outcomes
Change in Neuropsychiatric Inventory (NPI) apathy/indifference domain score
Time Frame: Up to 20 weeks
Pilot data from our two prior studies of oxytocin in FTD have driven the selection of the NPI as the primary outcome measure.
Secondary Outcomes
- Change in modified Clinicians Global Impression of Change (apathy) scores(Up to 20 weeks)
- Change in emotional facial expression recognition performance(Up to 20 weeks)
- Change in the Revised Self-Monitoring Scale score(Up to 20 weeks)